Contact

Iproteos and Oryzon: Spanish biotechs with the support of investors and progressing towards the market


, ,
Integral service around a transaction
BY : Diego GutiérrezNovember Wed, 2016
Good news for Spanish biotech, Iproteos has received a €1.5M round. Oryzon, which has been receiving venture capital backing since 2009, was able to go public last year and this week, after the good results published for its product, its share price has risen by 40%.
Iproteos recibe una ronda de €1,5M

La catalana  Iproteos,  que cuenta con varios proyectos en desarrollo en el campo de la esquizofrenia, la epilepsia y la aterosclerosis, ha cerrado una ronda de financiación de €1,5M liderada por Caixa Capital Risc y en la que también han participado Kinled Holding –empresa de inversión con sede en Hong Kong y oficinas en Londres, Nueva York y Zurich– y la biotecnológica ASCIL Biopharm.

Esta ronda permite a Ipotreos , que cuenta con varios productos en etapa pre-clínica poder avanzar hacia el mercado al  contar tanto con recursos económicos como con la  experiencia de agentes conocedores del sector.

Iproteos además cuenta con una tecnología propia,  IPROTech, una plataforma de vanguardia que combina herramientas informáticas y biotecnológicas desarrolladas por el propio equipo de investigación de Iproteos para el diseño de moléculas terapéuticas innovadoras, llamadas peptidomiméticos.

Anteriormente, Iproteos había realizado una ronda a través de una campaña de crowdfunding, de 100.000€.

Oryzon se dispara más de un 40% en bolsa por los avances  en su antitumoral en desarrollo, que dispone de un acuerdo con Roche

ma-tics-1

El precio de las acciones de Oryzon se disparó más del 40% el miércoles 15 de noviembre al haber obtenido resultado positivo en los primeros ensayos clínicos con pacientes de su antitumoral más avanzado, llamado ORY-1001.

En las sesiones del jueves y Viernes los inversores aprovecharon para hacer caja y la acción corrigió un 2%, pero en la jornada del lunes volvió a crecer.

Entre los inversores que han recogido beneficios está la Generalitat, a través de la empresa para la promoción y localización industrial de Cataluña Avançsa.  La Generalitat vendió acciones a 4,63€ por un importe total de 449.762€, lo que le ha servido para generar un beneficio de 212.264€.

La empresa cotizada cuenta con un acuerdo, el más importante de la biotecnología española, con Roche, por el que el laboratorio catalán recibirá hasta €500M de la multinacional suiza según se avance en la investigación clínica y en el lanzamiento al mercado de este fármaco. Con este hito, Oryzon ha concluido su parte de desarrollo de la molécula.

Oryzon, fundada en 2001 salió a bolsa en Diciembre de 2015, tras haber recibido dos rondas de inversión por valor de €28M.

 
If you are seeking funding, ponte en contacto con nosotros. Abra-Invest, cuenta con un equipo experto en financiación alternativa a tu disposición. Llama al + 34 946424142 o rellena el formulario de contacto.

 

Other posts that may interest you

Wallapop, Letgo and HallStreet: M&A Spanish companies to gain strength in international market

Diversion of venture capital in Spanish companies: Tyba and Otogami

 

The M&A Professionals

Meet our services

MEET
OUR
METODOLOGY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu